Login / Signup

Confirmation of the utility of the CA-125 elimination rate (KELIM) as an indicator of the chemosensitivity in advanced-stage ovarian cancer in a "real-life setting".

Lilian van WagensveldOlivier ColombanMaaike A van der AaGilles FreyerGabe S SonkeRoy F P M KruitwagenBenoit You
Published in: Journal of gynecologic oncology (2024)
The value of KELIM, as a pragmatic indicator of response to chemotherapy, was maintained in a large real-life population-based cohort, highlighting its applicability in routine conditions.
Keyphrases
  • clinical trial
  • study protocol
  • clinical practice
  • locally advanced
  • randomized controlled trial
  • squamous cell carcinoma
  • radiation therapy